Presentation Type:

Poster Presentation Subject Category: Antibiotic Stewardship

Evaluating the Prevalence of Leading Practices in Antimicrobial Stewardship

Barbara Braun; Salome Chitavi; Eddie Stenehjem; Mushira Khan; David Baker and David Hyun

Background: Most hospitals have a basic infrastructure in place for antimicrobial stewardship programs (ASPs). Although this is a critical first step, we need to ensure that ASPs are working to implement effective evidence-based approaches nationally. In 2018, a group of leading antibiotic stewardship organizations met and identified specific, effective, and recommended ASP activities based on current scientific evidence and their experience (Baker et al, Joint Comm J Qual Pat Saf 2019;45:517-523). To determine the extent to which hospitals are currently implementing the recommended practices, we conducted an electronic questionnairebased assessment. Methods: A 50-item questionnaire-based assessment was sent via QualtricsTM to the hospital's designated ASP leader. The sample comprised 992 Joint Commission accredited hospitals. The practices of interest related to (1) development of facility-specific treatment guidelines, (2) measuring appropriate use and concordance of care with these guidelines, (3) engaging clinicians while the patient is on the unit, (4) diagnostic stewardship, (5) measurement of antimicrobial utilization data, and (6) measuring hospital-acquired Clostridioides difficile infection (CDI) rates. Sampling weights were used to adjust the results for nonresponse using R software. Results: In total, 288 hospitals completed the questionnaire. Small and nonteaching hospitals were significantly less likely to respond (p < 0.005, p=0.01 respectively), however there were no differences by healthcare system membership or urban/rural location. 49% of respondents had the specialist term ASP or infectious disease (ID) in their title. Most hospitals (93.1%) had developed facility-specific treatment guidelines for specific inpatient conditions, often community-acquired pneumonia (85%), sepsis (81%), UTI (75%), and SSTI (69%). However, only 37% had formally assessed compliance with 1 or more of these guidelines. Also, 83% reported having a process for prospective audit and feedback, of which 43% do this 4-5 days per week. Similarly, 49% reported that they review all antimicrobials ordered. Recommendations are commonly given by the ASP pharmacist (69%) via some combination of telephone (78%), face-to-face (69%), text message (54%), and/or EHR alert (36%). Overall, 66% of hospitals had procedures in place to prevent inappropriate diagnostic testing for C. difficile, and 39% of hospitals had similar policies for urine specimens. Furthermore, >80% were routinely measuring days of therapy and CDI rates. Conclusions: Most hospitals have facility-specific treatment guidelines and measure CDI and days of therapy. Practices for active engagement with frontline staff in prospective audit and feedback vary widely. Greater understanding of barriers to assessing adherence to hospitals' treatment guidelines is critical to improving this practice. Funding: The Pew Charitable Trusts

Disclosures: None

Antimicrobial Stewardship & Healthcare Epidemiology 2021;1(Suppl. S1):s41 doi:10.1017/ash.2021.75

Presentation Type:

Poster Presentation Subject Category: C. difficile Clostridioides difficile Is Not Difficult to Predict in Hospital Settings Kinta Alexander; Frances Petersen and Sean Brown

Background: Clostridioides difficile is a gram-positive bacteria that is the most common cause of hospital-associated infectious diarrhea among traditional and nontraditional high-risk populations. Excess healthcare costs associate with *C. diff*icile infection (CDI) prevalence, morbidity, and mortality is shown to economically impact the US healthcare system with at least an additional \$1 billion in annual cost. Exposure to antimicrobial agents resulted in increased risk for hospital-onset CDI (HO-CDI) at an inner-city hospital during 2010 and 2011. **Methods:** A retrospective

case-control study of all persons with HO-CDI in the MICU was conducted at an inner-city hospital between January 1, 2010, and December 31, 2011. A patient was considered to have developed HO-CDI if diarrhea developed after 72 hours of admission into the MICU and a confirmed laboratory stool specimen for Clostridioides difficile infection (CDI) was obtained. A non-HO-CDI person was randomly selected using "risk set sampling." After the application of inclusion and exclusion criteria, 88 cases were eligible for the study. Of these cases, 29 met the definition for HO-CDI, and 59 met the definition for non-HO-CDI. The relationship between antimicrobial use and the development of HO-CDI in patients in the MICU at an inner-city hospital was investigated using a logistic regression model in which the variable of total antibiotics was used as a possible predictor for predicting a positive HO-CDI. Results: Logistic regression was utilized to determine the relationships between selected study variables and presence or absence of HO-CDI. Total antibiotics was significantly related to HO-CDI. The results of this analysis showed that total antibiotics was a significant predictor for HO-CDI. The total value of the coefficient B for this predictor was 0.47, and the exponentiated value (exp[B]) of this coefficient was 1.60 (95% CI, 1.08-2.35). In this sample, patients who had 1 or more antibiotics were at a 60% greater risk of having a positive HO-CDI culture. There was a significant association between the use of metronidazole and HO-CDI (p < .001). Conclusions: Antimicrobial stewardship is an integral part of patient safety. The findings from this study were instrumental in the implementation of a fledging antimicrobial stewardship program and the use of evidence-based practices at this inner-city hospital.

Funding: No

Disclosures: None

Antimicrobial Stewardship & Healthcare Epidemiology 2021;1(Suppl. S1):s41 doi:10.1017/ash.2021.76

Presentation Type:

Poster Presentation

Subject Category: C. difficile

Clinical Characteristics and Fecal Microbiome in Recurrent Versus Nonrecurrent *Clostridioides difficile* Infection

Swapnil Lanjewar; Ashley Kates; Lauren Watson and Nasia Safdar

Background: Up to 30% of patients with *Clostridioides difficile* infection (CDI) develop recurrent infection, which is associated with a 33% increased risk of mortality at 180 days. The gut microbiome plays a key role in initial and recurrent episodes of CDI. We examined the clinical characteristics and gut microbial diversity in patients with recurrent (rCDI) versus nonrecurrent CDI at a tertiary-care academic medical center. **Methods:** Stool samples were collected from 113 patients diagnosed with CDI between 2018 and 2019. Clinical and demographic data were extracted from the electronic

	Non-recurrent CDI (n = 58)	Recurrent CDI (n = 55)
Age in years, median (range)	58 (19 – 83)	59 (19 – 88)
Female, n (%)	38 (65.5)	30 (54.5)
Race, n (%)	Caucasian, 54 (93.1) African American, 3 (5.2) Other, 1 (1.7)	Caucasian, 50 (90.1) African American 3 (5.5) Other, 1 (1.8)
History of organ transplant, n (%)	6 (10.3)	12 (21.8)
Chronic kidney disease, n (%)	9 (15.5)	12 (21.8)
Diabetes Mellitus type 2, n (%)	8 (13.8)	11 (20)
Inflammatory bowel disease, n (%)	4 (6.9)	6 (10.9)
Appendectomy, n (%)	17 (29.3)	13 (23.6)
Smoker, n (%)	8 (13.8)	4 (7.3)
NSAID use, n (%)	17 (29.3)	16 (29.1)
PPI use, n (%)	21 (36.2)	16 (29.1)
Presence of chronic medical condition*, n (%)	36 (62.1)	34 (61.8)

* Congestive heart failure, liver cirrhosis, end stage renal disease, active malignancy, insulin dependent diabetes mellitus, autoimmune disease requiring immune suppression.

© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.